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2Abstract
 
Saudi Arabia is one of the countries that has been affected by COVID-19. At the beginning of 
March 2020, it revealed a steadily rising number of laboratory-confirmed cases. By 20th May 
2020, 59,854 infected cases had been confirmed, with 329 deaths. To prevent a further 
outbreak of COVID-19, this article discusses the current understanding of COVID-19 and 
compares it with the outbreak of Middle East Respiratory Syndrome (MERS) in 2012 in Saudi 
Arabia. It also discusses the causes, transmission, symptoms, diagnosis, treatments and 
prevention measures to identify an applicable measure to control COVID-19.
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31. Introduction
Within the last ten years, there have been two major outbreaks of coronavirus in Saudi Arabia. 
This first of these was in 2012, with the outbreak of Middle East Respiratory Syndrome-
coronavirus (MERS-CoV), which is known to have originated within Saudi Arabia via zoonotic 
transmission from dromedary camels. The second outbreak, which originated in Wuhan, 
Hubei province, China, in December 2019, was novel coronavirus-2019 (2019-nCoV), 
resulting in a disease identified as COVID-19. The latter has claimed and is still claiming the 
lives of many people around the world, leaving grieving family and friends, a fragile global 
economy, and frightened people with an uncertain future despite the extensive efforts in each 
country guided by the world health organization (WHO) (Lai et al., 2020). For example, the 
first reported case of MERS-CoV in the world was a male Saudi citizen who died of severe 
pneumonia and multiorgan failure in Jeddah in June 2012. In September 2012, it was 
identified that the disease was caused by a novel coronavirus, which was given the names 
nCoV and HCoV-EMC and later also became known as MERS-CoV (Zaki et al., 2012). 
However, a retrospective study carried out in November 2012 that tested stored respiratory 
and serum samples of patients who were victims of an outbreak of acute respiratory illness 
confirmed the presence of MERS-CoV cases as early as April 2012 in Zarqa, Jordan (Hijawi 
et al., 2013). In 2012, a Qatari patient confirmed to have MERS was taken to the United 
Kingdom (UK) for treatment, and in 2013, a severe case of MERS was confirmed to be a 
traveller returning from Pakistan and Saudi Arabia (Farooq et al., 2020). By 2019, the virus 
had spread not only across the Arabian Peninsula, but also globally, with the number of 
countries affected totalling 27 (Table 1).
Table 1. Countries with laboratory-confirmed cases of MERS-CoV infection by Centers for Disease 
Control and Prevention (CDC, 2019a).
Countries in or near the Arabian 
Peninsula that have reported MERS cases
Countries outside the Arabian 
Peninsula with travel-associated MERS 
cases
Saudi Arabia, Kuwait, Qatar, Oman, 
Bahrain, Oman, Yemen, United Arab 
Emirates, Jordan, Lebanon and Iran
Egypt, Tunisia, Algeria, Turkey, 
Greece, Italy, Netherlands, UK, 
Austria, France, Germany, Malaysia, 
China, Philippines, Republic of Korea, 
Thailand and United States of America 
(USA)
4Laboratory tests are still being performed for suspected cases, both in the Middle East and all 
over the world, for travellers returning from Middle Eastern countries owing to the high risk. 
The number of cases is still increasing, affecting hundreds of people around the world, which 
can largely be attributed to imported cases from the Middle East. Statistics reveal that the 
number of people infected and the number of deaths caused by MERS-CoV are continuing to 
increase. According to WHO, between the outbreak in 2012 and the end of January 2020, 
MERS-CoV had infected 2,519 people globally, resulting in 866 associated deaths, a case 
fatality rate (CFR) of 34.3%. The highest number of cases was reported by Saudi authorities: 
2,121 cases with 788 related deaths, and the CFR peaked at 37.1% (WHO, 2020).
Similarly, the current outbreak of 2019-nCoV, which originated in Wuhan, has spread across 
the world. While the swift decision by China to implement a lockdown meant that the country 
had managed to control the spread, it seems that fresh waves of infection are still a possibility. 
Furthermore, the disease is continuing to spread in many other countries. As of 20th May 2020, 
4,761,559 confirmed cases and 317,525 deaths had been reported in 215 countries and 
territories, translating into a CFR of 6.66% (WHO, 2020c). A total of 59,854 cases and 329 
deaths (CFR of 0.55%) have been reported by Saudi Arabia, which is far more than the total 
number of worldwide cases reported for MERS (WHO, 2020a). This substantial difference in 
the incidence of disease is probably due to the lower infection rate (R0) of MERS, potentially 
owing to its greater severity and mortality rate. 2019-nCoV is a mild upper respiratory illness 
that may develop into severe interstitial pneumonia and finally into Acute Respiratory Distress 
Syndrome (ARDS) (Song et al., 2019). Despite the similarity among different coronaviruses, 
COVID-19 shows different pathogenetic, epidemiological and clinical features to MERS-CoV, 
a phenomenon that is not yet fully understood. In response to the recent COVID-19 outbreak, 
this paper reviews the latest data available for MERS and evaluates the preventative 
measures described in the literature. The aim of this paper is to obtain knowledge and apply 
it to the current COVID-19 outbreak in Saudi Arabia. Since Saudi Arabia attracts a high 
number of visitors and is the place of pilgrimage for Muslims around the world, poor control 
and a lack of preventative measures may lead to the disease spreading locally and 
internationally. Therefore, this paper will discuss in depth the origin, risk factors, clinical and 
pathological features, laboratory characteristics, prevention measures and current 
developments in the treatment of MERS and COVID-19.
52. History and Emergence of Human Coronaviruses (HCoVs)
HCoVs develop crown-like spikes on the surface and belong to the Coronaviridae family and 
subfamily. They are a group of highly diverse, single-stranded, positive-sense ribonucleic acid 
viruses with an envelope (Shereen et al., 2020). These viruses are responsible for respiratory, 
hepatic, gastrointestinal and neurological diseases of varying severity in a wide range of 
animal species, including humans. There are four different genera of coronaviruses: αCoV, 
βCoV, γCoV, and δCoV (Zumla et al., 2016). The history of HCoVs can be traced back to the 
1960s, when 229E and OC43 were some of the first HCoVs confirmed to cause respiratory 
infections in humans. Despite several reports identifying that these viruses cause lower 
respiratory tract infection, it was generally believed that coronaviruses had 
low pathogenicity until the emergence of severe acute respiratory syndrome coronavirus 
(SARS-CoV) in 2002. The SARS outbreak in Guangdong province, China, in November 2002 
resulted in more than 8,400 cases with a fatality rate more than 10% (Bleibtreu et al., 2019a). 
Figure 1. The timeline of identified HCoVs that have infected people (CDC, 2020)
Later, the HCoVs NL63 and HKU1 were identified in 2004 and 2005 respectively but could not 
be replicated in the laboratory. Recently, confirmed cases caused by MERS-CoV and 2019-
nCoV were identified in 2012 and 2019 respectively (Figure 1) (Hui, 2017; Song et al., 2019). 
The phylogenetic analysis of 2019-nCoV revealed that it is closely related to (88–89% 
similarity) two bat-derived SARS-like coronaviruses, namely bat-SL-CoVZC45 and bat-SL-
CoVZXC21. Conversely, it is very dissimilar to SARS-CoV and MERS-CoV, displaying a 
difference of 79% and 50% respectively .
63. Causes
MERS
MERS-CoV is a zoonotic virus, which means it is transmitted between animals and humans. 
Studies have confirmed that people can be infected via direct or indirect contact with infected 
dromedary camels. According to WHO (2019), MERS-CoV has been reported in dromedaries 
in several regions, including the Middle East, Africa, Europe, and South Asia. The outbreak of 
MERS-CoV is attributed to the dromedary camel trade between numerous Arabian Peninsula 
regions in addition to other countries such as Kenya, Nigeria, Tunisia, Burkina Faso, Sudan, 
Egypt Ethiopia and Morocco (Corman et al., 2014; Müller et al., 2014; Miguel et al., 2017). 
Although the origin of the virus is not fully clear, it is believed that it may have originated in 
bats and was later spread to camels sometime in the distant past (Song et al., 2019; Farooq 
et al., 2020; Killerby et al., 2020). Interestingly, studies on dromedary camel serum collections 
dating as far back as 1983−1997 indicated that anti-MERS-CoV or anti-MERS-like CoV 
antibodies were present in the serum, indicating that MERS-CoV may have been widespread 
in East African countries such as Somalia, Sudan and Egypt as far back as the date of the 
samples (Müller et al., 2014). Furthermore, a phylogenetic analysis discovered the presence 
of five different coronavirus lineages in camels, including the recombinant lineage causing the 
MERS epidemic (Sabir et al., 2016; Bleibtreu et al., 2019a). Subsequently, in 2012, Saudi 
Arabia registered the first human death from MERS-CoV: a 60-year-old man who died of 
respiratory and renal failure only 11 days after being admitted to hospital in Jeddah (Zaki et 
al., 2012). By September of the same year, a case was confirmed in the UK, where a patient 
suffered a severe respiratory infection associated with MERS-CoV after travelling to the 
Middle East (Bermingham et al., 2012). In both cases, it was possible to duplicate the virus in 
an in vitro tissue culture model, and it was then isolated and identified (Zaki et al., 2012). 
Furthermore, in April 2013, two healthcare professionals working in an intensive care unit 
(ICU) died from MERS-CoV infection at Al Zarqa Hospital in Jordan (WHO, 2012). The human-
to-human transmission of MERS continues to spread through community clusters and/or in 
healthcare settings worldwide (Table 2). Confirmed cases of MERS are still being reported to 
WHO by many countries (WHO, 2020b).
COVID-19
In many ways, COVID-19 is not very different from MERS since it is caused by a zoonotic 
virus that belongs to the same family of HCoVs. Studies indicate that 2019-nCoV occurred at 
a live animal market in China, and it was realised that it was transmitted between an animal 
and a human in late 2019 (Bogoch et al., 2020; Lu, Stratton and Tang, 2020). 
7Table 2. Epidemiology characteristics of COVID-19 and MERS-CoV across the globe and in the 
Kingdom of Saudi Arabia (KSA) (up to 20th of May 2020) (WHO, 2020c).
Epidemiology 
Characteristics
MERS-CoV COVID-19
Original Location Jeddah, Saudi Arabia Wuhan, China
Outbreak 12 countries 215 countries and 
territories
Global Total Cases
(KSA)
2,553
 (2,121) 
up to 31st March 2020
4,761,559+
(59,854+)
Global Total Deaths
(KSA)
876
 (788)
up to 31st March 2020
(317,525+)
(329+)
Healthcare Worker Cases 
(%)
18.6 3.8
Reproductive Number <1.00 >3.28
Incubation Period (Days) 4.5 - 5.2 4.75 - 6.4
Serial Interval (Days) 12.6 2.6 - 7.5
Global CFR %
 (KSA)
34.30
(37.10)
6.66
(0.55)
CFR with Comorbidities 
(%)
60.0 73.3
The developed pneumonia was interpreted as the emergence of novel coronavirus, and it was 
first called SARS-CoV-2. On 30th of January 2020, WHO declared the outbreak of COVID-19 
to be a ‘public health emergency of international concern’. On 2nd of March 2020, just 32 days 
after the WHO declaration, the Saudi Ministry of Health (SMOH) confirmed the first COVID-
19 case in the country in a traveller who had returned from the Islamic Republic of Iran. Initially, 
the cases recorded in Saudi Arabia occurred in the east of the country in people who had a 
recent travel history to Iran via Bahrain. A week later, the number of laboratory-confirmed 
8cases amplified and has been rising since then. The majority of the cases were non-Saudi 
residents who had returned from abroad. On 24th of March, the SMOH reported the first death 
from COVID-19 in Al-Madinah Al-Menorah in Saudi Arabia, with 767 cases confirmed. The 
person who died was an elderly resident who was a Pakistani national (Wegaya, 2020). 
4. The trend of the MERS outbreak
The outbreak of MERS-CoV spread rapidly in many cities in Saudi Arabia. Owing to its high 
infectivity rate, many healthcare professionals who had been in contact with the infected 
patients were infected with it. Furthermore, the MERS-CoV outbreak was observed in nearby 
countries, such as Kuwait, Jordan, Qatar and Bahrain, and as far as Tunisia. Healthcare 
systems in the above-mentioned countries responded quickly to the reports of these 
epidemics. Indeed, although a few patients developed mild infections, the MERS fatality rate 
was high at >34.3% (Bleibtreu et al., 2019a). Although the MERS epidemic had spread to over 
27 countries, none were affected as severely as Saudi Arabia, which had reported more than 
71% of the total confirmed cases, as shown in Table 2. Unlike SARS-CoV that disappeared 
less than two years after evolving, MERS-CoV has not disappeared, and seven years later, it 
still poses a threat. For example, the SMOH reported to WHO that ten new cases of MERS-
CoV infections, which included one fatality, occurred between 1st and 30th of November 2019. 
These cases were found in different regions, including Riyadh (four), Madinah (two), Al-
Qassim (one), Assir (one), Taif (one), and Makkah (one). To date, WHO continues to receive 
reports of hospital outbreaks among healthcare workers, patients and visitors (WHO, 2020). 
It can be said that MERS-CoV has the ability to spread among humans after direct or indirect 
contact with dromedary camels. MERS-CoV causes severe pneumonia that increases the rate 
of mortality (Song et al., 2019; Killerby et al., 2020). However, the government of Saudi Arabia 
continues to monitor the outbreak and epidemiological situation of MERS and conducts risk 
assessments based on the latest available information provided by WHO.
5. The trend of the COVID-19 outbreak
As mentioned above, the outbreak of COVID-19 started in Wuhan, China, in late December 
2019. Subsequently, the virus spread rapidly throughout the globe, including Saudi Arabia, 
where the first case was confirmed on 2nd of March 2020. With the world having become a 
global village, this puts into perspective the ease of the spread of the virus. The fast growth 
and ease of commercial air travel and limited specific cures or vaccines available for HCoV 
infections led to its rapid spread (Lai et al., 2020). To date, COVID-19 has caused tens of 
9thousands (>317,529) of fatalities, which include both the young and the old. With the current 
lack of antivirals for COVID-19, the vital factors that determine the recovery of a patient include 
the immune system of the individual and the availability of artificial respiratory devices. As 
mentioned earlier, COVID-19 is on the rise in Saudi Arabia. The authorities have identified 
returning travellers as the carriers of COVID-19 and the main reason for its outbreak. 
Moreover, gatherings of these visitors with local residents, such as in family gatherings and 
holly places, have been a major contributor to the spread of the disease within the population. 
The data in Table 2 suggests that 2019-nCoV was able to rapidly spread among the population 
despite the strong measures implemented by the authorities. The national dashboard of data 
for the number of confirmed cases still displays a daily increasing trend of confirmed cases in 
all regions, especially around the centre and west of the country. For example, on 31st of 
March, the SMOH reported 1,563 confirmed cases with ten deaths. Ten days later, the number 
of confirmed cases increased to 3,651 with 47 deaths, while on 21st of April, the number of 
people infected and the number of deaths increased dramatically to 11,631 and 109 
respectively. To date, despite the 24-hour early quarantine and lockdown policies applied (on 
15th of March), the number of confirmed cases are still growing.
Most importantly, the trend of the COVID-19 outbreak in Saudi Arabia and the rest of the world 
has had other devastating effects. These include economic instability and challenges related 
to sustainability, especially in countries like the USA, the UK, and other countries in Europe. 
Consequently, on 11th of March 2020, WHO declared that this COVID-19 outbreak was the 
sixth public health emergency of international concern, following H1N-2009, polio-2014, 
Ebola-2014 in West Africa, Zika-2016, and Ebola-2019 in the Democratic Republic of Congo. 
Therefore, governments, healthcare professionals, leaders and the public need to cooperate 
on a global level to develop effective strategies to stop the COVID-2019 outbreak (Yoo, 2020).
6. Transmission
MERS
Although several field surveys on many types of animals, both domestic and wild, including 
dromedary camels (Camelus dromedarius), Bactrian camels (Camelus bactrianus), cattle, 
sheep, chickens, swine, ducks, bats, buffalo, goats and equids, have been conducted, the 
exact mode of transmission of MERS-CoV to humans is not yet fully understood. However, 
epidemiologic, genetic and phenotypic studies suggest that dromedary camels might be the 
main intermediary reservoirs of MERS-CoV (Azhar et al., 2014; Reusken et al., 2014; 
Conzade et al., 2018). It has been reported that MERS-CoV can survive in camel’s milk for 
long periods, although no viable virus is detected after pasteurisation at 63°C for longer than 
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half an hour. Therefore, it is believed that camels are the intermediary host species for MERS-
CoV. However, to date, the origin and the mode of transmission in many primary MERS cases 
remain uncertain. Although some people support the hypothesis that bats are the primary 
source of transmission of MERS-CoV infections to humans, not enough data supports this 
hypothesis. For example, studies have found MERS-CoV-specific antibodies in dromedary 
camels in many countries, with the exception of the Netherlands (Reusken et al., 2013), 
Australia (Hemida et al., 2014) and Kazakhstan (Miguel et al., 2016). Moreover, a study of 
more than 1,000 samples from Taphozous bats found only one fragment of the virus that 
closely matched the human isolate (Memish et al., 2013).
The human-to-human transmission of MERS-CoV can occur within households and 
communities, and especially within hospitals. The largest MERS-CoV outbreaks within 
healthcare settings occurred in Saudi Arabia, followed by the United Arab Emirates and the 
Republic of Korea (Azhar et al., 2019). According to the WHO report on MERS in December 
2019, among a total of 17 new laboratory-confirmed cases globally, 15 cases were reported 
by Saudi Arabia, with five associated deaths (WHO, 2020). Although studies indicate that 
MERS-CoV does not appear to transmit easily from person to person unless there is close 
contact, such as providing clinical care (Drosten et al., 2014; Korea Centers for Disease 
Control and Prevention, 2015; Zumla, Hui and Perlman, 2015; Kim et al., 2017; Azhar et al., 
2019), <50% of infected patients can transmit the virus to other individuals they come into 
contact with (Hui et al., 2018). The strong measures implemented to prevent MERS-CoV 
infection in hospital settings and nosocomial outbreaks is highly important. Despite the 
available knowledge, more studies need to be conducted to determine whether MERS-CoV is 
transmitted via direct or indirect contact, airborne droplets or ingestion (Azhar et al., 2014). 
WHO expects further cases of MERS-CoV infection to emerge in the Middle East and that the 
infection will continue to be exported to other countries by individuals who might develop the 
infection after exposure to dromedary camels or an infected individual. Until an effective 
vaccine is discovered, it is vital to increase public awareness of the disease and educate them 
on the prevention measures to limit the risk of its transmission and thus avoid another outbreak 
of MERS-CoV (Killerby et al., 2020). 
COVID-19 
2019-nCoV is the third zoonotic coronavirus to cause an outbreak in the 21st century. It is a 
highly contagious virus that is transmitted rapidly among people, which led to a global 
pandemic. Similar to the previous outbreaks of coronaviruses, SARS-CoV and MERS-CoV, 
which were transmitted from bats to palm civets or dromedary camels and finally to humans, 
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2019-nCoV is also believed to have an intermediate host in its route from bats to humans (Xie 
and Chen, 2020). It has been suggested that pangolins are a potential intermediate host since 
they have high similarity to the virus genome, 85.5% to 92.4%, representing two sub-lineages 
of novel coronavirus in the phylogenetic tree (Lam et al., 2020). In another study, it was found 
that 2019-nCoV is a recombinant of bat and snake coronaviruses when compared  with 
relative synonymous codon among different animal species (Ji et al., 2020). Further 
confirmation that 2019-nCoV was transmitted to humans through animals comes from its link 
to fish and wild animal markets (CDC, 2019b). Nevertheless, after having infected a human, 
the recent outcomes and new cases of infections confirm that 2019-nCoV can be transmitted 
from human to human through direct contact (Shereen et al., 2020; Shim et al., 2020). Studies 
also showed that the virus is capable of spreading via respiratory droplets from a distance of 
2 metres or even via contaminated surfaces (Lai et al., 2020). The Saudi data centre reveals 
a daily increase in the number of new confirmed COVID-19 cases being transmitted within 
families and within the healthcare setting to healthcare workers. 
Table 3. The key characteristics of 2019-nCoV
2019-nCoV Characteristics 
1. It is more contagious than to MERS-CoV.
2. It has minor differences in the genome sequences compared with SARS-CoV.
3. It has a higher binding affinity with angiotensin-converting enzyme 2 (ACE2) 
receptor than SARS-CoV.
4. Its fatality rate is lower than that of MERS-CoV.
5. It is detected in the stools of infected patients, similar to SARS-CoV and MERS-
CoV.
6. The viral load is higher at the time of onset of symptoms and decreases 
progressively during the clinical course of the disease.
7. Only 1.2% of confirmed cases are asymptomatic.
8. There are less frequent clinical complications in 2019-nCoV than in MERS-CoV.
9. Demographic characteristics and laboratory and radiological findings of COVID-
19 are not very different from those of MERS-CoV.
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Moreover, the transmission of 2019-nCoV via the gastrointestinal route has been confirmed, as 
was the case for MERS-CoV (Petrosillo et al., 2020). For example, 2019-nCoV was found in 
gastrointestinal tract specimens (stool and rectal swabs), saliva and urine, and even in 
oesophageal erosion and the bleeding site of patients with severe peptic ulcer (Xie and Chen, 
2020). This was explained by the great binding affinity (∼15 nM) of 2019-nCoV with ACE2, which 
is 10- to 20-fold higher than ACE2’s binding affinity with SARS-CoV (Wrapp et al., 2020). 
According to the recent reports published by the SMOH and WHO, human-to-human transmission 
is the main cause of the large-scale transmission of COVID-19 infection. The reproductive number 
(R0) estimated by WHO for COVID-19 is between 2 and 2.5, which is higher than that of SARS-
CoV (1.7–1.9) and MERS (<1). However, other studies have estimated a much higher R0 value 
of 4 (Chen, 2020). This might explain the rapid development of COVID-19 and its ability to transmit 
on a global scale at a much faster rate than MERS. 
Furthermore, the School of Public Health of the University of Hong Kong recently confirmed that 
a patient’s dog was infected with a low level of 2019-nCoV via its nasal and oral cavity, with no 
prior signs of disease. This might be the first confirmed human-to-animal transmission, which 
explains the high transmissibility of the disease from and to animals (El Zowalaty and Järhult, 
2020). It also highlights the potential need to socially isolate not only from fellow human beings, 
but also from pets. Despite all the available data on COVID-19, the exact mechanism of 2019-
nCoV transmission is not fully understood.
Consequently, the world, including Saudi Arabia, has witnessed a lockdown, which was 
unimaginable by the majority only a few months earlier. Countries have closed their borders, public 
events have been cancelled, and people have been asked to stay at home and leave only if 
absolutely necessary. After the initial outbreak in China, when the stringent lockdown measures 
were implemented, there was a decrease in the number of infected cases in China, with the 
majority having recovered (Shereen et al., 2020). However, in Saudi Arabia, although the number 
of cases seems to have plateaued somewhat, it is still not decreasing. The outbreak seems to be 
concentrated in highly populated cities such as Riyadh, Jeddah, Makkah and Al Madinah (CDC, 
2020). On 14th of March, Saudi authorities imposed a 12-hour curfew to fight the outbreak of 
COVID-19 in all cities and governorates. Following this, on 6th of April, further measures in the 
form of a 24-hour curfew and a lockdown were imposed on the cities of Riyadh, Tabuk, Dammam, 
Dhahran and Hofuf, as well as the governorates of Jeddah, Taif, Qatif and Khobar. These actions 
were taken to support the efforts made by the Kingdom to confront the coronavirus pandemic.
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To sum up, the current 2019-nCoV seems to have relatively low pathogenicity but high 
transmissibility compared with earlier HCoVs (Chen, 2020). Table 3 illustrates the main 
characteristic of 2019-nCoV. The average incubation period for COVID-19 can be as along as 5 
days, while the quarantine period should be 14 days from the last exposure date. This is the 
longest incubation period compared with similar types of HCoVs. However, the incubation period 
remains a topic of debate in the literature, as incubation periods of up to 27 days or above have 
been proposed by some studies (Chen, 2020; Shim et al., 2020).
7. Clinical features
The unique symptoms of any infection make the identification and detection of the disease 
easier for differential diagnosis with other viral diseases. However, the absence of specific 
clinical features for MERS-CoV infection makes this task a major challenge (Garbati et al., 
2016; Mohd et al., 2016). This leads to delays in deploying the precautions that would prevent 
potential secondary contamination (Bleibtreu et al., 2019a). Along with this, it can result in 
medical confusion and inappropriate patient management (Bleibtreu et al., 2018). The clinical 
features of MERS are very variable, which makes it difficult for differential diagnosis with 
other viral respiratory diseases. These features range from no symptoms to a flu-like 
syndrome, pneumonia and ARDS (Mohd et al., 2016; Aleanizy et al., 2017). Likewise, the 
clinical features of COVID-19 greatly resemble viral pneumonia caused by SARS and MERS. 
The majority of COVID-19 cases are mild (81%) with self-limiting features and those infected 
usually recover in two weeks (Wu and McGoogan, 2020). Most people (about 80%) recover 
from the disease without needing special treatment. Approximately 1 out of 6 COVID-19 
patients become seriously ill and have breathing difficulties (WH0, 2020). The most common 
symptoms of MERS and COVID-19 include fever, cough, fatigue, sore throat and dyspnoea. 
Digestive system disorders (diarrhoea) and acute renal failure are associated with MERS, 
whereas rhinorrhoea, sneezing, ground-glass opacity, blood disorders and bilateral 
pneumonia are more likely to be symptoms of COVID-19 (Xie and Chen, 2020). Patients with 
COVID-19 suffer more respiratory symptoms than patients with MERS (Xie and Chen, 2020; 
Yi et al., 2020; Yoo, 2020) . Table 4 summarises the systemic and respiratory disorders related 
to MERS and COVID-19.
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Table 4. The main symptoms of MERS and COVID-19.
MERS COVID-19
Systemic 
Disorders
Cough, Fever, Headache, 
Tiredness, Sputum production, 
Myalgia, Diarrhoea, Digestive 
system signs, Chills, Arthralgia, 
Odynophagia, Haemoptysis, 
Acute renal failure, Multi-organ 
failure.
Dry cough, Fever, 
Headache, Tiredness, 
Sputum production, 
Myalgia, Diarrhoea (2% 
of patients), 
Haemoptysis, 
Lymphopenia, Blood 
disorders. 
Respiratory 
Disorders
Sore throat, Dyspnoea, 
Haemoptysis, Rapid 
development of pneumonia, 
ARDS
Sore throat, Rhinorrhoea 
and Sneezing, 
Pharyngalgia, Dyspnoea, 
Haemoptysis, Bilateral 
pneumonia, Ground-
glass opacity, 
Pneumonia, ARDS. 
8. Diagnosis
The optimal test for the diagnosis of HCoV infections is the reverse transcription polymerase 
chain reaction test (RT-PCR). Other medical investigations such as serology tests and 
computed tomography (CT) scans can also be used as supporting diagnostic tests in most 
cases, but are often used for second-line diagnostic investigation.
MERS
The PCR-based detection method is presently the best available technique for the 
identification of the virus in a respiratory sample, and also for the detection of infections 
caused by MERS-CoV. Several other clinical specimens, such as sputum, endotracheal 
aspirate, bronchoalveolar lavage, nasal or nasopharyngeal swabs, faeces, urine, blood and 
lung tissue can also be used to diagnose the type of infection (Hui et al., 2018; Azhar et al., 
2019). Serology tests can also be performed and they are particularly useful for cases that 
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have a high suspicion of MERS-CoV, but have negative PCR results. These include serum 
neutralisation assays (Müller et al., 2015), microarrays (Reusken et al., 2013) and 
newly enzyme-linked immunosorbent assay (ELISA) confirmed by a micro-neutralisation 
test (Trivedi et al., 2018). These tests are normally able to detect the relevant antibodies ten 
days after the disease develops (Mohd et al., 2016; Xie et al., 2020). Blood tests can therefore 
reveal if the person was previously infected, indicated by the presence of MERS-CoV 
antibodies (Medical News Today, 2020). Additionally, radiographic results can indicate 
infection with MERS. Significant radiographic features include bilateral hilar infiltration, 
unilateral or bilateral patchy densities or infiltrates, segmented or lobar opacities, ground-glass 
opacities and small pleural effusions (Hui, 2017).
Covid-19 
Similar to MERS, RT-PCR is the most widely used technique for COVID-19 detection. 
Additionally, other possible methods of diagnosing COVID-19 are immune identification 
technologies, such as point-of-care testing (POCT) of IgM/IgG, and ELISA, but further study 
is needed (Chen, 2020; Xie and Chen, 2020). Patients infected with COVID-19 often appear 
to have abnormal chest CT scans, demonstrating bilateral pulmonary parenchymal ground-
glass, rounded consolidative pulmonary opacities and a peripheral lung distribution, which can 
aid in a differential diagnosis (Petrosillo et al., 2020).
9. Treatment
To date, no approved specific antiviral agents have been available for current or previous 
outbreaks of HCoVs, but convalescent sera or monoclonal antibodies which inhibit SARS-CoV 
or MERS-CoV are currently under development in vitro and in animal testing (Yi et al., 2020; 
Zhang et al., 2020). Beside using existing antivirals and other possible drugs, the overall 
treatment strategies involve: 1) maintaining the internal environment (i.e. water, electrolytes 
and other internal environment factors), 2) observing vital signs (e.g. heart rate, pulse, 
respiratory rate, blood pressure and oxygen saturation) and 3) ensuring sufficient energy 
intake (62.63).
MERS
Some therapeutic options against various viral elements are currently available, whilst others 
are under development (McKimm-Breschkin et al., 2018). Examples of different classes of 
treatments are: 1) immunotherapy with anti-MERS-CoV antibodies, 2) molecules with antiviral 
activities, 3) symptomatic treatment preventive therapies and 4) vaccines, although these are 
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currently under development (Azhar et al., 2019). Table 6 shows the anti-MERS-CoV agents 
that are currently being used. Combination treatments have also been used, e.g. Interferon-α 
(IFN-α) with antiviral or protease inhibitors or mycophenolate mofetil (Hui, 2017). A 
retrospective study in Saudi Arabia on MERS-CoV patients with refractory respiratory failure 
showed that, as with other respiratory infections, it is necessary to use extracorporeal 
membrane oxygenation (ECMO) as salvage treatment for those who suffer respiratory failure. 
In regards to the use of chloroquine, no supportive studies are available at the present time 
(12.65).
COVID-19 
The global need for a specific anti-COVID-19 drug has led to great efforts to accelerate the 
search for an effective antiviral agent. The current treatment employed for COVID-19 does not 
differ greatly from the MERS treatment management approach, e.g. broad-spectrum antivirals 
are used as first line treatments (Wang et al., 2020). A list of anti-COVID-19 agents that have 
been used is presented in Table 5. 
Table 5. The potential treatments for MERS and COVID-19
Anti-MERS-CoV agents used Anti-Covid-19 agents used
Intravenous Immunoglobulins Oseltamivir
Interferon-α Interferon-α
Ribavirin Ritonavir
Lopinavir Lopinavir
Protease inhibitors Ganciclovir
Mycophenolate mofetil Remdesivir
Nitazoxamide Ribavirin
Alisporivir Remidisvir
Chloroquine Arbidol
Silvestrol Chloroquine
Corticosteroids Tocilizumab
Examples of potential treatments for COVID-19 are IDX-184, Sofosbuvir & EIDD-2801 
(isopropyl ester of N4-hydroxycytidine) 
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Potential compounds undergoing further investigation include EIDD-2801 (isopropyl ester of 
N4-hydroxycytidine), Sofosbuvir and IDX-184. Along with these, Ribavirin and Remidisvir may 
potentially have a high therapeutic value in treating COVID-19 (Barnard et al., 2006; Lajoie et 
al., 2017; Vincent et al., 2005). Due to the absence of evidence, the WHO’s interim guidelines 
(from the 22nd February 2020) do not support the use of systemic corticosteroids for the 
treatment of viral pneumonia and ARDS in suspected COVID-19 cases. However, the efficacy 
and associated adverse effects of glucocorticoids in COVID-19 treatment currently need 
further elucidation (Zhang et al., 2020). Many firms are developing vaccines for the COVID-
19 virus. The vaccine (ChAdOx1 nCoV-19) that has been developed by the University of 
Oxford and backed by the UK government has already been given to the first two candidates 
in Oxford, England, on the 23rd April 2020. Furthermore, around 1,100 people are expected to 
be injected with the vaccine as part of the trial (BBC, 2020). The vaccine was prepared by the 
serum institute in India by removing the harmful properties of the pathogen to decrease its 
virulence, whilst at the same time keeping it alive. However, more time is needed to obtain 
enough data to know if the vaccine works. Vaccine trials are already ongoing in China and the 
USA, and are due to commence in Germany at the end of the current month (Sarvepalli, 2020). 
For now, most patients are receiving antiviral therapy in addition to ventilation support to 
manage COVID-19 symptoms (D. Wang et al., 2020).
10. Sequelae
A sequela is the lingering effect formed after the acute phase of an illness or injury has 
disappeared. There is no time limit on when a sequela can develop. For example, a sequela 
might appear early in cerebral infarction, or it may be delayed by months or years, due to a 
previous injury (Petrignani et al., 2018).
MERS
A cohort study that assessed the health-related quality of life of 78 survivors who required 
hospitalisation in Saudi Arabia between 2016 and 2017 found that MERS survivors 
experienced a degree of lung impairment (Batawi et al., 2019). The study reported the 
presence of impairment in the diffusion capacity of the lungs for carbon monoxide up to 
2 years after recovery. In addition, changes in air space were evident through chest 
radiographs and high-resolution CT scans. MERS survivors also described significant 
weakening in physical health at approximately 14 months after illness compared to a 
previously published sample of healthy individuals in Saudi Arabia. As many MERS patients 
admitted to ICU were given high doses of corticosteroids, the sequelae from this type of 
therapy could contribute to reduced quality of life in survivors (Bleibtreu et al., 2018). 
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Corticosteroid-induced myopathy, muscle wasting and weakness has also been previously 
reported among SARS-CoV survivors (Herridge et al., 2003; Ng et al., 2004). Additionally, the 
study revealed that critically ill MERS survivors had emotional damage which might be due to 
psychological trauma. Similar findings were reported from South Korea, where 73 survivors 
who had suffered from severe pneumonia developed significant impairments in pulmonary 
function compared to those with mild or no pneumonia (Park et al., 2018). 
COVID-19
As of the 20th May, about 1,804,347 cases (37.34%) worldwide had recovered from COVID-
19. Researchers believe that those who recover can be left with damaged lungs. However, it 
is too early to confirm any long-term effects. Investigators in Hong Kong and China analysed 
more than 152 lung scans of recovered patients and found ground glass opacity in both lungs, 
in addition to fluid or debris filled sacs in the lungs. It is expected that with these sequelae, the 
long-term effects are likely to progressively worsen. Another report on the sequelae of COVID-
19 indicates that 20-30% of recovered COVID-19 patients suffer a decline in lung capacity 
due to irreversible lung fibrosis (Cox, 2020). COVID-19 has also caused scarring and stiffening 
of the lung tissue. Permanent damage to the lungs may progress into severe respiratory issues 
and ARDS (Wang et al., 2020). Moreover, anxiety, depression and trauma-related symptoms 
have been associated with HCoV outbreaks (Troyer, Kohn and Hong, 2020). It is believed that 
older patients may be less able to return to their pre-illness state, whereas the chance of lung 
tissue recovery is higher for younger patients. Therefore, there is also a need to study the 
long-term impact of COVID-19 to establish a framework for treatment.
11. Prevention
Saudi Arabia has implemented rapid and effective infection control and isolation measures to 
prevent the spread of MERS and COVID-19. These measures are focused on 4 main aspects: 
confirmed cases, close contact handling, community prevention and protection of healthcare 
workers.
MERS
Confirmed cases
Approximately 2.519 laboratory confirmed cases of infection with MERS-CoV were registered 
for the period from June 2012 to January 2020, according to the WHO. Around 866 of these 
cases were associated with deaths (WHO, 2020b). Although transmission of the disease is 
not fast, SMOH advises taking all possible measures and that suspected cases should be 
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quarantined prior to having a laboratory test result, which takes between 12 and 24 hours. 
This is crucial to combat the spread of MERS to a new family member or a healthcare worker 
(Altamimi et al., 2020). Mild symptomatic cases that result in a positive PCR may be dealt with 
by isolation at home, whereas severe to moderate cases should be isolated in hospital until 
they recover, and then discharged for isolation at home for an extended period. Both mild and 
severe cases are re-tested after 7 days, and the test is subsequently repeated every 3 days 
until a negative result is obtained (Garbati et al., 2016). The WHO have stated that the ongoing 
efforts to combat MERS transmission have been successful in reducing the prevalence of 
MERS-CoV (WHO, 2020b).
Close contact handling 
All close contacts of MERS patients were required to report to selected medical centres by the 
Department of Health for close contact handling. Home quarantine measures were suggested 
for those in close contact with a suspected case in a bid to reduce the possibility of MERS-
CoV transmission.
Community prevention 
Patients with both suspected and confirmed cases of MERS‐CoV are advised to visit one of 
the specialised testing centres to detect community transmission. In addition, public education 
is provided regarding infection prevention and control and updated regularly via social media. 
This includes the use of face masks, hand hygiene, disinfection of surfaces for fomites, 
avoiding direct contact with infected people, covering the mouth with a tissue when coughing 
or sneezing and other simple hygiene measures (Garbati et al., 2016). The authorities have 
also warned of the dangers of consuming raw or undercooked animal products, including milk 
and meat, as they may have a high risk of MERS-CoV infection. The advice is not to have 
direct contact with camel excretions and subsequently touch mucous membranes, as this can 
be a key source of infection. Three specialised centres have been set up in the Kingdom to 
deal with these cases (22.51) .
Protection of healthcare workers
Healthcare workers are told to use personal protective equipment (PPE), i.e. N95 masks, face 
shield or goggles, gloves and isolation gowns as strict infection control measures to prevent 
droplet and contact transmission. It is not always possible to identify patients with MERS-CoV 
infection early. This is due to the fact that, like other respiratory infections, the early symptoms 
of MERS-CoV are non-specific. Therefore, SMOH emphasises that healthcare workers should 
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always apply standard precautions consistently with all patients. Additionally, patients with 
confirmed cases are advised to wear a mask to avoid further spread of the virus via droplets. 
When providing care to patients with symptoms of acute respiratory infection, contact 
precautions and eye protection should be used. In line with the WHO, SMOH encourages all 
healthcare units to continue surveillance for new MERS cases and to carefully review any 
unusual patterns.
COVID-19
Confirmed cases
During early March 2020, the Saudi Center for Disease Prevention and Control (Wegaya) 
indicated the need for urgent isolation and quarantine during the COVID-19 outbreak in the 
country. It is advised that suspected COVID-19 patients should be placed in an area separated 
from other patients. Extra precautions should promptly be implemented when dealing with 
patients to avoid getting ill, as the disease is able to transmit rapidly from human to human. 
All confirmed cases are kept in hospital for isolation and treatment until fully recovered. 
Suspected cases are also required to quarantine at home until a negative result is confirmed 
via PCR testing. To find high risk cases on admission to hospital, from March 2020, the 
patient’s travel history is collected from the immigration department and incorporated into the 
hospital authority computer system (Clinical Management System). Temperature checking is 
maintained as a routine check for arrivals into Saudi Arabia along with 14 days of quarantine. 
Additionally, respiratory specimens have been collected from all travellers and sent for viral 
testing at regional SMOH laboratories since the 15th March 2020 (Al-Tawfiq and Memish, 
2020) . 
Close contact handling 
Suspected cases and close contacts are required to self-isolate for 14 days at home or in their 
accommodation and monitor their daily body temperature, signs and symptoms (Al-Tawfiq and 
Memish, 2020; Yezli and Khan, 2020).
Community prevention 
In accordance with the recommendations of the health authorities, Saudi has applied proactive 
preventive measures to reduce the spread of COVID-19 within the community. For example, 
on the 26th of February 2020, Saudi Arabia temporarily suspended entry to individuals seeking 
to perform the Umrah pilgrimage to Mecca or visit the prophet’s Mosque in Medina. 
Furthermore, this restriction applied to all tourists travelling from countries with an extensive 
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spread of COVID-19. Subsequently, on the 8th of March, all schools and universities were 
locked down. All public events, prayers, holy sites for Muslims, public museums, public 
libraries, sports centres and venues were either closed or cancelled to avoid clusters of 
infections. Visitors or those returning to the Saudi international airports were taken to stay in 
a quarantine centre (5-star hotel) for a period of two weeks. This was applied on the 9th of 
March 2020. Following this, on the 15th of March 2020, Saudi Arabia prohibited entry to all 
travellers, so all local and international airports have been locked down to date. Likewise, 
public services and cross-border transportation have also been suspended. Saudi Arabia 
imposed a dusk to dawn curfew on the 23rd of March 2020, meaning that people were only 
allowed to leave their homes between 6 am and 7 pm. After the number of confirmed deaths 
had increased to 38, the duration of these daily curfews was extended to 24 hours for 5 cities 
and 4 governorates on the 7th of April. Similar measures were imposed on several more cities 
later in the same month (78.79). Recently, curfews have been eased across the country, but 
24-hour lockdowns are still in place in Mecca and neighbouring areas. Outside Mecca and the 
lockdown areas, curfews will be eased between 9 am and 5 pm until the 22nd May. Authorities 
now plan to enforce a nationwide 24-hour curfew during the 5-day Muslim festival of Eid Al-
Fitr, starting on the 23rd of May.
Protection of healthcare workers
Healthcare workers exposed to a COVID-19 case are required to respect international 
guidelines approved by SMOH and the WHO to limit the spread of COVID-19. All healthcare 
workers are advised to use personal protective equipment (PPE), especially those who have 
direct exposure to patients with suspected or confirmed COVID-19. Every person in a public 
hospital is required to wear a surgical mask to prevent cross contamination (Yezli and Khan, 
2020).
12. Hajj & Umrah in the time of COVID-19
Saudi Arabia is a place of pilgrimage and therefore is an important religious gathering place 
for Muslims. One of the largest religious gatherings is the Hajj and Umrah, which is likely to 
provide serious challenges in terms of outbreak containment. Hajj is an annual Islamic ritual 
attended by over two million Muslims from more than 188 countries, so during the outbreak 
there is a risk of mass exposure and spread all over the world (Atique and Itumalla, 2020). 
This could facilitate the spread of COVID-19 to multiple countries, including those that have 
been less affected so far, whilst also re-spreading to countries that have recovered or are 
recovering from the outbreak. Muslims also travel to Saudi for Umrah (mini-pilgrimage) which 
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requires similar considerations to those mentioned above. As a result, it is strongly advised 
that the prevailing situation with regard to COVID-19 should be observed and evaluated by 
the Ministry of Hajj and Umrah in Saudi Arabia, along with religious scholars, to make 
appropriate decisions about the next Hajj which is fast approaching (July 2020). Potential 
measures with regard to this are vital for further mitigation of the pandemic (Farooq et al., 
2020). To successfully limit the extent of the COVID-19 outbreak, the following points are 
recommended:
1. Above all, prevent or reduce the transmission from the natural host. This requires more 
knowledge of the natural ecology of the virus. Such transmission risks should be 
considered when new contact between bats and humans takes place, or when human 
settlements extend into bat habitats. Also, social science can be employed to better 
convey the message to the general public regarding interactions with specific animals, 
and when to avoid these (based on disease ecology knowledge) (Lu et al., 2020).
2. Prevent or reduce the risk of transmission from the intermediate host. In principle, this 
risk could be avoided by completely separating the primary host from the intermediate 
host (e.g. bats from camels). This will depend on which animal or animals are proven 
to constitute the intermediate host or hosts for COVID-19. However, in practice this 
may prove to be difficult, since live animal markets appear to play an important role in 
this process. These could be a starting point for measures to be employed with a true 
One Health approach (Lu, Milinovich and Hu, 2016).
3. Reduce transmission between humans. This is a crucial measure to prevent further 
development of the outbreak, and is currently the primary measure employed, for good 
reason (Bleibtreu et al., 2019b).
13. Conclusion
The MERS epidemic began in 2012 and outbreaks have subsequently been seen worldwide. 
Although MERS-CoV continues to persist in the Middle East 7 years later, MERS has not 
become pandemic. In contrast, COVID-19 emerged in December 2019 and spread rapidly 
throughout the whole world within a few weeks ( ten weeks). On the 11th of March 2020, 
COVID-19 was declared a pandemic by the WHO (WHO, 2020a). The latest data available on 
causes, transmissions, symptoms, treatments and preventive measures of MERS and 
COVID-19 have been reviewed. However, more information on the biology, epidemiological 
features, diagnosis and treatments of various HCoVs are urgently required to further advance 
the risk assessment and response. This will ultimately have benefits for the control and 
prevention of the current COVID-19 pandemic. RT-PCR testing, as a diagnostic tool, is used 
to confirm infection with MERS or COVID-19. However, this may sometimes provide a false 
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negative result. To date, there are no specific treatment regimens or vaccines for HCoVs, and 
the only antiviral therapy currently employed is broad spectrum. However, a number of 
antiviral drugs targeting specific HCoVs, along with vaccines, are under development (Jiang, 
Du and Shi, 2020; Yu et al., 2020). The WHO has shipped millions of items of personal 
protective equipment to 105 countries, as well as lab supplies to more than 127 countries. 
This, however, requires the joint efforts of the public, politicians and scientists. Social 
distancing, personal hygiene and protection are the most significant and important measures 
for controlling transmission. This includes wearing a mask, washing hands, decreasing social 
contact, avoiding crowds and working from home, as well as following the instructions 
provided by local health authorities and the WHO (Bleibtreu et al., 2019a). 
Fear plays a role in economic and social consequences, and this is also a feature of the SARS-
CoV outbreak. The human, economic and social crisis created by the COVID-19 pandemic 
may also increase global unemployment, inequality, exclusion, discrimination and general 
unrest in the medium and long term, if not properly addressed. In the meantime, therefore, 
educating the population and strengthening public confidence will be critical.
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